- Home
- LUNG vs ATAI Comparison
LUNG vs ATAI Comparison
Compare LUNG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- ATAI
- Stock Information
- Founded
- LUNG 1995
- ATAI 2018
- Country
- LUNG United States
- ATAI Germany
- Employees
- LUNG N/A
- ATAI N/A
- Industry
- LUNG Industrial Specialties
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- ATAI Health Care
- Exchange
- LUNG Nasdaq
- ATAI Nasdaq
- Market Cap
- LUNG 124.0M
- ATAI 444.7M
- IPO Year
- LUNG 2020
- ATAI 2021
- Fundamental
- Price
- LUNG $2.87
- ATAI $2.61
- Analyst Decision
- LUNG Buy
- ATAI Strong Buy
- Analyst Count
- LUNG 6
- ATAI 2
- Target Price
- LUNG $11.53
- ATAI $11.00
- AVG Volume (30 Days)
- LUNG 317.8K
- ATAI 5.9M
- Earning Date
- LUNG 07-30-2025
- ATAI 08-12-2025
- Dividend Yield
- LUNG N/A
- ATAI N/A
- EPS Growth
- LUNG N/A
- ATAI N/A
- EPS
- LUNG N/A
- ATAI N/A
- Revenue
- LUNG $87,473,000.00
- ATAI $1,863,000.00
- Revenue This Year
- LUNG $18.02
- ATAI $554.22
- Revenue Next Year
- LUNG $18.17
- ATAI N/A
- P/E Ratio
- LUNG N/A
- ATAI N/A
- Revenue Growth
- LUNG 19.84
- ATAI 572.56
- 52 Week Low
- LUNG $2.50
- ATAI $1.03
- 52 Week High
- LUNG $9.37
- ATAI $2.99
- Technical
- Relative Strength Index (RSI)
- LUNG 39.07
- ATAI 58.55
- Support Level
- LUNG $2.62
- ATAI $2.62
- Resistance Level
- LUNG $2.88
- ATAI $2.99
- Average True Range (ATR)
- LUNG 0.17
- ATAI 0.23
- MACD
- LUNG 0.05
- ATAI 0.02
- Stochastic Oscillator
- LUNG 39.68
- ATAI 58.89
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.